View ValuationNeuRizer 将来の成長Future 基準チェック /06現在、 NeuRizerの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長27.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 21NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listingお知らせ • Feb 18NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listingお知らせ • Feb 08NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million. Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 159,800,000 Price\Range: AUD 0.001 Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 147,000,000 Price\Range: AUD 0.001 Transaction Features: Subsequent Direct ListingBoard Change • Feb 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 22NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct ListingBoard Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 11NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million.NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million. Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 306,800,000 Price\Range: AUD 0.001 Transaction Features: Subsequent Direct Listingお知らせ • Oct 30NeuRizer Ltd., Annual General Meeting, Nov 28, 2024NeuRizer Ltd., Annual General Meeting, Nov 28, 2024.New Risk • Jul 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (54% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$14.3m market cap, or US$9.62m).New Risk • May 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (42% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$3.80m market cap, or US$2.52m).Board Change • Apr 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Company Secretary & Non-Executive Director Jordan Mehrtens was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 12NeuRizer Ltd. Appoints Jordan Mehrtens as Non-Executive DirectorNeuRizer Ltd. announce that Ms Jordan Mehrtens has been appointed as a non-executive Director of the Company, effective 11 February 2024. Ms Mehrtens is the Company Secretary and has been for the past 9 years, with the key terms of her employment agreement detailed below. Ms Mehrtens is a qualified Lawyer and has a Bachelor of Commerce (Finance) and a Graduate Diploma in Urban and Regional Planning. Ms Mehrtens has worked with the NeuRizer Urea Project since its commencement, providing regulatory, compliance and other analytical advice. Ms Mehrtens is a member of the Governance Institute of Australia (GIA) and holds a Certificate in Governance Practice from the GIA.New Risk • Jan 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 25% per year over the past 5 years. Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Revenue is less than US$1m. Market cap is less than US$10m (AU$9.65m market cap, or US$6.34m). Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Shareholders have been diluted in the past year (24% increase in shares outstanding).お知らせ • Jan 16Neurizer Ltd. Announces Executive ChangesNeuRizer Ltd. announced that as a result of a corporate review the position of Managing Director has been made redundant. The Executive Chairman will assume the duties previously undertaken by the Managing Director. Assuch Phil Staveley will cease being the Managing Director of NRZ on the 15th of January 2024.お知らせ • Dec 20NeuRizer Ltd. Announces Step Down of Murray Chatfield from the BoardNeuRizer Ltd. advised that after more than 7 years as non-executive director, Mr. Murray Chatfield has decided to step down from the NeuRizer Board effective immediately. Murray joined the board in 2015 as an independent director. In that time he has provided valuable input and guidance to the Company. His endless energy, vast knowledge of financial markets and products combined with a passion for relevant targeted innovation has been a valuable and deep resource for NeuRizer. Murray attended every board and audit committee meeting over his 7 years and has always worked to ensure that the best interests of shareholders were at the forefront in the decision making of the Company.New Risk • Nov 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$34.5m market cap, or US$21.9m).お知らせ • Oct 11NeuRizer Ltd., Annual General Meeting, Nov 10, 2023NeuRizer Ltd., Annual General Meeting, Nov 10, 2023, at 09:30 Cen. Australia Standard Time. Agenda: To consider the financial report and the reports of the Directors and of the Auditors for the financial year ended 30 June 2023; to consider adoption of the Remuneration Report for the year ended 30 June 2023; to consider re-election of Directors of the Company; to consider approval to issue Placement Shares; to consider ratification of the issue of shares for March and September Placement Shares; to consider ratification of the issue of options to March Broker Options; to consider Issue of Options to Zhe Wang, Zheng Xiaojiang and Murray Chatfield in lieu of pay; and to consider approval of additional 10% Placement Capacity.New Risk • Oct 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$47.0m market cap, or US$30.2m).お知らせ • Sep 06NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.05 Transaction Features: Subsequent Direct Listingお知らせ • Aug 01NeuRizer Ltd. Announces Change of DirectorsNeuRizer Ltd. announced that Mr. Sunghun Ryu has been appointed as a Non-Executive Director of the Company, effective 31 July 2023. This follows the resignation of Mr. Jaehyung Yoo from the Board of NRZ. Mr. Yoo joined the NRZ Board in August 2022 and has resigned due to a change in Mr. Yoo's role at DL E&C Co. Ltd. (DL E&C). Mr. Ryu is the Vice President of Strategy & Planning, Plant Business Division of DL E&C.Recent Insider Transactions • Jun 09MD & Director recently sold AU$194k worth of stockOn the 1st of June, Phillip Staveley sold around 2m shares on-market at roughly AU$0.097 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Phillip's only on-market trade for the last 12 months.お知らせ • May 10NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,285,714 Price\Range: AUD 0.07 Transaction Features: Subsequent Direct ListingBoard Change • Mar 01Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Wang Zhe was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、NeuRizer は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CHIA:NRZ - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2024N/A-6-6-4N/A3/31/2024N/A-7-9-5N/A12/31/2023N/A-8-13-6N/A9/30/2023N/A-12-23-8N/A6/30/2023N/A-16-34-9N/A3/31/2023N/A-19-28-10N/A12/31/2022N/A-22-21-11N/A9/30/2022N/A-21-19-10N/A6/30/2022N/A-20-16-10N/A3/31/2022N/A-19-21-8N/A12/31/2021N/A-18-26-6N/A9/30/2021N/A-16-17-6N/A6/30/2021N/A-14-8-5N/A3/31/2021N/A-11-11-8N/A12/31/2020N/A-8-14-11N/A9/30/2020N/A-8-11-9N/A6/30/2020N/A-7-9-6N/A3/31/2020N/A-8-8-3N/A12/31/2019N/A-8-70N/A9/30/2019N/A-9-121N/A6/30/2019N/A-10-173N/A3/31/2019N/A-9-193N/A12/31/2018N/A-8-214N/A9/30/2018N/A-7-200N/A6/30/2018N/A-6-19-3N/A3/31/2018N/A-6N/A-3N/A12/31/2017N/A-5N/A-3N/A9/30/2017N/A-6N/A-4N/A6/30/2017N/A-6N/A-5N/A3/31/20170-6N/A-4N/A12/31/20160-6N/A-4N/A9/30/20160-6N/A-4N/A6/30/2016N/A-5N/A-4N/A3/31/20160-12N/A-3N/A12/31/20150-19N/A-2N/A9/30/20150-19N/A-2N/A6/30/20150-18N/A-1N/A6/30/201400N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NRZの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NRZの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NRZの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NRZの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NRZの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NRZの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/06/11 02:14終値2025/03/14 00:00収益2024/06/30年間収益2024/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NeuRizer Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Sanjeev BahlEdison Investment ResearchStuart RobertsPitt Street Research Pty Ltd.
お知らせ • Feb 21NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 18NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 133,333,333 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 08NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.3068 million. Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 159,800,000 Price\Range: AUD 0.001 Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 147,000,000 Price\Range: AUD 0.001 Transaction Features: Subsequent Direct Listing
Board Change • Feb 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 22NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 0.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: AUD 0.0015 Transaction Features: Subsequent Direct Listing
Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Manyoo Han was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 11NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million.NeuRizer Ltd. has filed a Follow-on Equity Offering in the amount of AUD 0.3068 million. Security Name: Oridnary Shares Security Type: Common Stock Securities Offered: 306,800,000 Price\Range: AUD 0.001 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 30NeuRizer Ltd., Annual General Meeting, Nov 28, 2024NeuRizer Ltd., Annual General Meeting, Nov 28, 2024.
New Risk • Jul 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (54% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$14.3m market cap, or US$9.62m).
New Risk • May 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Share price has been highly volatile over the past 3 months (42% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$3.80m market cap, or US$2.52m).
Board Change • Apr 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Company Secretary & Non-Executive Director Jordan Mehrtens was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 12NeuRizer Ltd. Appoints Jordan Mehrtens as Non-Executive DirectorNeuRizer Ltd. announce that Ms Jordan Mehrtens has been appointed as a non-executive Director of the Company, effective 11 February 2024. Ms Mehrtens is the Company Secretary and has been for the past 9 years, with the key terms of her employment agreement detailed below. Ms Mehrtens is a qualified Lawyer and has a Bachelor of Commerce (Finance) and a Graduate Diploma in Urban and Regional Planning. Ms Mehrtens has worked with the NeuRizer Urea Project since its commencement, providing regulatory, compliance and other analytical advice. Ms Mehrtens is a member of the Governance Institute of Australia (GIA) and holds a Certificate in Governance Practice from the GIA.
New Risk • Jan 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 25% per year over the past 5 years. Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Revenue is less than US$1m. Market cap is less than US$10m (AU$9.65m market cap, or US$6.34m). Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Shareholders have been diluted in the past year (24% increase in shares outstanding).
お知らせ • Jan 16Neurizer Ltd. Announces Executive ChangesNeuRizer Ltd. announced that as a result of a corporate review the position of Managing Director has been made redundant. The Executive Chairman will assume the duties previously undertaken by the Managing Director. Assuch Phil Staveley will cease being the Managing Director of NRZ on the 15th of January 2024.
お知らせ • Dec 20NeuRizer Ltd. Announces Step Down of Murray Chatfield from the BoardNeuRizer Ltd. advised that after more than 7 years as non-executive director, Mr. Murray Chatfield has decided to step down from the NeuRizer Board effective immediately. Murray joined the board in 2015 as an independent director. In that time he has provided valuable input and guidance to the Company. His endless energy, vast knowledge of financial markets and products combined with a passion for relevant targeted innovation has been a valuable and deep resource for NeuRizer. Murray attended every board and audit committee meeting over his 7 years and has always worked to ensure that the best interests of shareholders were at the forefront in the decision making of the Company.
New Risk • Nov 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (AU$34.5m market cap, or US$21.9m).
お知らせ • Oct 11NeuRizer Ltd., Annual General Meeting, Nov 10, 2023NeuRizer Ltd., Annual General Meeting, Nov 10, 2023, at 09:30 Cen. Australia Standard Time. Agenda: To consider the financial report and the reports of the Directors and of the Auditors for the financial year ended 30 June 2023; to consider adoption of the Remuneration Report for the year ended 30 June 2023; to consider re-election of Directors of the Company; to consider approval to issue Placement Shares; to consider ratification of the issue of shares for March and September Placement Shares; to consider ratification of the issue of options to March Broker Options; to consider Issue of Options to Zhe Wang, Zheng Xiaojiang and Murray Chatfield in lieu of pay; and to consider approval of additional 10% Placement Capacity.
New Risk • Oct 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$47.0m market cap, or US$30.2m).
お知らせ • Sep 06NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.05 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 01NeuRizer Ltd. Announces Change of DirectorsNeuRizer Ltd. announced that Mr. Sunghun Ryu has been appointed as a Non-Executive Director of the Company, effective 31 July 2023. This follows the resignation of Mr. Jaehyung Yoo from the Board of NRZ. Mr. Yoo joined the NRZ Board in August 2022 and has resigned due to a change in Mr. Yoo's role at DL E&C Co. Ltd. (DL E&C). Mr. Ryu is the Vice President of Strategy & Planning, Plant Business Division of DL E&C.
Recent Insider Transactions • Jun 09MD & Director recently sold AU$194k worth of stockOn the 1st of June, Phillip Staveley sold around 2m shares on-market at roughly AU$0.097 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Phillip's only on-market trade for the last 12 months.
お知らせ • May 10NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million.NeuRizer Ltd. has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,285,714 Price\Range: AUD 0.07 Transaction Features: Subsequent Direct Listing
Board Change • Mar 01Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Wang Zhe was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.